Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3

References

• De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436(7053)953–960
   PubMed Web of Science ®Google Scholar
• Steinkühler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998; 37(25)8899–8905
   PubMed Web of Science ®Google Scholar
• Llinàs-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998; 8(13)1713–1718
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426(6963)186–189
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair LA, Purdy S, Chu H-M, Jansen PLM. Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology (New York) 2005; 42(233A), abst 96
   Google Scholar
• Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler DL, Zhang J. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (Peg-IFN-a). Hepatology 2005; 42(233A), abst 94
   PubMed Web of Science ®Google Scholar
• Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48(6)2260–2266
   PubMed Web of Science ®Google Scholar
• Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279(17)17508–17514
   PubMed Web of Science ®Google Scholar
• Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70(2)28–38
   PubMed Web of Science ®Google Scholar
• Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280(44)36784–36791
   PubMed Web of Science ®Google Scholar
• Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41(4)832–835
   PubMed Web of Science ®Google Scholar
• Mehdi S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg chem 1993; 21: 249–259
   Web of Science ®Google Scholar
• Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1997; 7(11)1353–1363
   Web of Science ®Google Scholar
• Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinàs-Brunet M, Nar H, Lamarre D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl 2003; 42(12)1356–1360
   PubMed Web of Science ®Google Scholar
• Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50(3)899–909
   PubMed Web of Science ®Google Scholar
• Johansson A, Poliakov A, Åkerblom E, Wiklund K, Lindeberg G, Winiwarter S, Danielson UH, Samuelsson B, Hallberg A. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase). A comparative study of different C-terminals. Bioorg Med Chem 2003; 11: 2551–2568
   PubMed Web of Science ®Google Scholar
• Llinàs-Brunet M, Bailey M, Déziel R, Fazal G, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J, Thibeault D, Wernic D, Lamarre D. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998; 8(19)2719–2724
   PubMed Web of Science ®Google Scholar
• Poliakov A, Johansson A, Åkerblom E, Oscarsson K, Samuelsson B, Hallberg A, Danielson UH. Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors. Biochim Biophys Acta 2004; 1672(1)51–59
   PubMed Web of Science ®Google Scholar
• Narjes F, Brunetti M, Colarusso S, Gerlach B, Koch U, Biasiol G, Fattori D, De Francesco R, Matassa VG, Steinkühler C. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry 2000; 39(7)1849–1861
   PubMed Web of Science ®Google Scholar
• Llinàs-Brunet M, Bailey M, Fazal G, Ghiro E, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J, Thibeault D, Wernic D, Lamarre D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg Med Chem Lett 2000; 10(20)2267–2270
   PubMed Web of Science ®Google Scholar
• Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004; 47(7)1605–1608
   PubMed Web of Science ®Google Scholar
• Oscarsson K, Poliakov A, Oscarson S, Danielson UH, Hallberg A, Samuelsson B. Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): Model compounds towards small molecule inhibitors. Bioorg Med Chem 2003; 11(13)2955–2963
   PubMed Web of Science ®Google Scholar
• Poliakov A, Hubatsch I, Shuman CF, Stenberg G, Danielson UH. Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of hepatitis C virus. Protein Expr Purif 2002; 25: 363–371
   PubMed Web of Science ®Google Scholar
• Fersht A. Structure and mechanism in protein science. A guide to enzyme catalysis and protein folding. W.H. Freeman and Company, New York 1999
   Google Scholar
• Urbani A, Bazzo R, Nardi MC, Cicero DO, De Francesco R, Steinkühler C, Barbato G. The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation. J Biol Chem 1998; 273(30)18760–18769
   PubMed Web of Science ®Google Scholar
• Perni RB, Britt SD, Court JC, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Kim JL, Landro JA, Levin RB, Luong YP, O'Malley ET, Pitlik J, Rao BG, Schairer WC, Thomson JA, Tung RD, Van Drie JH, Wei Y. Inhibitors of hepatitis C virus NS3.4A protease 1. non-charged tetrapeptide variants. Bioorg Med Chem Lett 2003; 13(22)4059–4063
   PubMed Web of Science ®Google Scholar
• Di Marco S, Rizzi M, Volpari C, Walsh MA, Narjes F, Colarusso S, De Francesco R, Matassa VG, Sollazzo M. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000; 275(10)7152–7157
   PubMed Web of Science ®Google Scholar
• Perni RB, Pitlik J, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Levin RB, Lin C, Lin K, Moon YC, Luong YP, O'Malley ET, Rao BG, Thomson JA, Tung RD, Van Drie JH, Wei Y. Inhibitors of hepatitis C virus NS3.4A protease 2. warhead SAR and optimization. Bioorg Med Chem Lett 2004; 14(6)1441–1446
   PubMed Web of Science ®Google Scholar
• Johansson A, Poliakov A, Åkerblom E, Lindeberg G, Winiwarter S, Samuelsson B, Danielson UH, Hallberg A. Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase). Bioorg Med Chem 2002; 10(12)3915–3922
   PubMed Web of Science ®Google Scholar
• Koch U, Biasiol G, Brunetti M, Fattori D, Pallaoro M, Steinkühler C. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: Electrostatic precollision guidance and transition-state stabilization. Biochemistry 2001; 40(3)631–640
   PubMed Web of Science ®Google Scholar